```
=> d his

     (FILE 'HOME' ENTERED AT 17:11:26 ON 13 MAR 2006)

     FILE 'REGISTRY' ENTERED AT 17:11:32 ON 13 MAR 2006
                E GABAPENTIN/CN
L1              1 S E3

     FILE 'CAPLUS' ENTERED AT 17:12:46 ON 13 MAR 2006
L2           1615 S L1 OR GABAPENTIN OR  GO(W)3450 OR GOE(W)2450 OR  GOE(W)3450 O
L3              3 S L2(L)(CARTILAGE OR OSTEROARTHRITIS OR MATRIX(3A)METALLOPROTEA

     FILE 'USPATFULL, USPAT2' ENTERED AT 17:17:33 ON 13 MAR 2006
L4            369 S L3
L5             72 S L4 NOT PY>=2003
L6              5 S L4 NOT PY>=2002

     FILE 'MEDLINE' ENTERED AT 17:21:59 ON 13 MAR 2006
L7              0 S L6
```

```
=> s e3
L1             1 GABAPENTIN/CN

=> d rn str cn

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   60142-96-3  REGISTRY
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

CN   Cyclohexaneacetic acid, 1-(aminomethyl)- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   1-(Aminomethyl)cyclohexaneacetic acid
CN   CI 945
CN   Gabapentin
CN   Go 3450
CN   GOE 2450
CN   GOE 3450
CN   Neurontin
```

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:225063 CAPLUS
DOCUMENT NUMBER: 142:385432
TITLE: Oral treatment with PD-0200347, an α2δ ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes
AUTHOR(S): Boileau, Christelle; Martel-Pelletier, Johanne; Brunet, Julie; Tardif, Ginette; Schrier, Denis; Flory, Craig; El-Kattan, Ayman; Boily, Martin; Pelletier, Jean-Pierre
CORPORATE SOURCE: Notre-Dame Hospital, University of Montreal Hospital Centre, Montreal, QC, Can.
SOURCE: Arthritis & Rheumatism (2005), 52(2), 488-500
CODEN: ARHEAW; ISSN: 0004-3591
PUBLISHER: John Wiley & Sons, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Objective: To examine the in vivo effects of PD-0200347, an α2δ ligand of voltage-activated Ca2+ channels and a compound chemical related to pregabalin and **gabapentin**, on the development of **cartilage** structural changes in an exptl. dog model of osteoarthritis (OA). The effects of PD-0200347 on the major pathways involved in OA **cartilage** degradation, including matrix metalloproteinases (MMPs) and the inducible form of nitric oxide synthase (iNOS), were also studied. Methods: OA was surgically induced in dogs by sectioning the anterior cruciate ligament. OA dogs were randomly distributed into 3 groups and treated orally with either (1) placebo, (2) 15 mg/kg/day of PD-0200347, or (3) 90 mg/kg/day of PD-0200347. Dogs were killed 12 wk after surgery. The severity of the lesions was scored macroscopically and histol. **Cartilage** specimens from the femoral condyles and tibial plateaus were processed for RNA extraction and quant. reverse transcription-polymerase chain reaction (RT- PCR) or immunohistochem. Specific probes and antibodies were used to study the mRNA and protein levels of iNOS, MMP-1, MMP-3, and MMP-13. Results: No clin. signs of drug toxicity were noted in the treated animals. Treatment with PD-0200347 at both dosages tested (15 and 90 mg/kg/day) reduced the development of **cartilage** lesions. There was a reduction in the score of lesions, with a statistically significant ($P = 0.01$) difference when the highest dosage of the drug was administered. The reduction in the score was mainly related to a decrease in the surface size of the lesions. Quant. RT-PCR showed that PD-0200347 significantly reduced the expression of MMP-13, a key mediator in OA. Immunohistochem. analyses showed that treatment with PD-0200347 significantly reduced the synthesis of all key OA mediators studied. Conclusion: This study demonstrated the efficacy of PD-0200347 in reducing the progression of **cartilage** structural changes in a dog model of OA. It also showed that this effect is linked to the inhibition of the major pathophysiol. mediators responsible for **cartilage** degradation
REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:678656 CAPLUS
DOCUMENT NUMBER: 139:202522
TITLE: Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
INVENTOR(S): Taylor, Charles Price, Jr.
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070237	A1	20030828	WO 2003-IB534	20030212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2476438	AA	20030828	CA 2003-2476438	20030212
AU 2003246864	A1	20030909	AU 2003-246864	20030212
EP 1480639	A1	20041201	EP 2003-742460	20030212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007906	A	20041221	BR 2003-7906	20030212
JP 2005523281	T2	20050804	JP 2003-569193	20030212
US 2003199567	A1	20031023	US 2003-366798	20030214
NO 2004003947	A	20040921	NO 2004-3947	20040921
PRIORITY APPLN. INFO.:			US 2002-359295P P	20020222
			US 2002-404365P P	20020819
			WO 2003-IB534 W	20030212

AB The invention relates to a combination, comprising a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, and a ligand for calcium channel α2δ subunit, or a pharmaceutically acceptable salt thereof, and valdecoxib. Examples of selective inhibitors of COX-2 include valdecoxib, rofecoxib, and celecoxib. Examples of α2δ ligands include **gabapentin**, pregabalin, (3S,4S)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, and 3-(1-aminomethyl-cyclohexymethyl)-4H-[1,2,4]oxadiazol-5-one hydrochloride (I). The combinations are useful for treating certain diseases including **cartilage** damage, inflammation, pain, and arthritis. For example, capsules containing 25 mg each of valdecoxib and I were prepared

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:314397 CAPLUS
DOCUMENT NUMBER: 136:335265
TITLE: Method of treating cartilage damage
INVENTOR(S): Schrier, Denis; Welgus, Howard Glenn; Wustrow, David Juergen
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: Eur. Pat. Appl., 138 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1199072	A2	20020424	EP 2001-124081	20011010
EP 1199072	A3	20030319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002072533	A1	20020613	US 2001-952787	20010914
US 6620829	B2	20030916		
NZ 514738	A	20030829	NZ 2001-514738	20011010
AU 780283	B2	20050310	AU 2001-79378	20011012
CA 2358802	AA	20020417	CA 2001-2358802	20011015
ZA 2001008494	A	20030416	ZA 2001-8494	20011016
JP 2002167329	A2	20020611	JP 2001-319435	20011017
US 2004097405	A1	20040520	US 2003-602413	20030623
PRIORITY APPLN. INFO.:			US 2000-241119P P	20001017

AB The invention relates to a method of preventing or treating cartilage damage by administering a GABA analog such as, for example, a compound of Formula H2NCH2C[(CH2)n]CH2CO2R1 and pharmaceutically acceptable salts thereof, wherein R1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.